<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813276</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY21020095</org_study_id>
    <nct_id>NCT04813276</nct_id>
  </id_info>
  <brief_title>Efficacy of a Self-advocacy Serious Game Intervention</brief_title>
  <official_title>Efficacy of a Self-advocacy Serious Game Intervention for Women With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals with cancer must overcome multiple, ongoing challenges (&quot;self-advocate&quot;) related&#xD;
      to their cancer experience to receive patient-centered care. Women with metastatic breast or&#xD;
      advanced gynecologic cancer often face significant challenges managing their quality of life&#xD;
      concerns and cancer- and treatment-related symptoms. If they do not self-advocate to manage&#xD;
      these concerns, they risk having poor quality of life, high symptom burden, and care that is&#xD;
      not patient-centered. Serious games (video games that teach) are effective health&#xD;
      interventions that allow users to vicariously engage in situations reflecting their personal&#xD;
      experiences, receive meaningful information, and learn personally relevant skills that they&#xD;
      can apply in real life.&#xD;
&#xD;
      The goal of the current study is to test the efficacy of a novel intervention using a serious&#xD;
      game platform to teach self-advocacy skills to women with metastatic breast or advanced&#xD;
      gynecologic cancer. The Strong Together intervention consists of a multi-session, interactive&#xD;
      serious game application with tailored self-advocacy goal-setting and training. The serious&#xD;
      game is based on a self-advocacy conceptual framework and applies behavior change theories&#xD;
      and serious game mechanisms to promote skill development and implementation. The game works&#xD;
      by immersing users in the experiences of characters who are women with advanced cancer;&#xD;
      requiring users to make decisions about how the characters self-advocate; demonstrating the&#xD;
      positive and negative consequences of self-advocating or not, respectively; and providing&#xD;
      multiple, individualized feedback mechanisms and game features to enforce self-advocacy skill&#xD;
      acquisition and transference to real life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient-centered care (e.g., incorporating patient preferences, needs, and values into all&#xD;
      care aspects) is an essential component of high-quality care, associated with improved&#xD;
      patient health, well-being, treatment adherence, and care coordination. Patients cannot&#xD;
      participate in patient-centered care if they do not have the skills to self-advocate.&#xD;
      Self-advocacy is defined as the ability to overcome health challenges by making informed&#xD;
      healthcare decisions, communicating effectively with healthcare providers, and gaining&#xD;
      strength through connection to others. Our work established that self-advocacy is associated&#xD;
      with higher quality of life, lower symptom burden, higher patient-centered care, and fewer&#xD;
      hospital admissions and emergency visits. Self-advocacy is particularly necessary in the&#xD;
      advanced cancer setting where patients face numerous health challenges including complex&#xD;
      treatment decisions, multiple cancer- and treatment-related symptoms, and poor quality of&#xD;
      life. However, many patients struggle to self-advocate because they have not previously&#xD;
      needed these skills or do not know how to apply these skills within their cancer experience.&#xD;
      Interventions to teach patients self-advocacy are lacking, and the few programs that exist&#xD;
      rely on non-interactive patient education that does not leverage behavior change or&#xD;
      educational theories. There is a critical need for theoretically grounded interventions to&#xD;
      teach patients with advanced cancer self-advocacy skills so that they can address health&#xD;
      challenges related to their care and experience improved outcomes.&#xD;
&#xD;
      Technology-based serious games (educational video games) allow users to vicariously engage in&#xD;
      situations reflecting their personal experiences, receive meaningful information, and learn&#xD;
      personally relevant skills that they can apply in real life. Serious games are an ideal&#xD;
      platform for teaching self-advocacy skills because they use immersive, motivational elements&#xD;
      and mechanisms to provide highly-relevant skills-training. Serious games improve patient&#xD;
      knowledge and skills though their mechanisms of action remain unclear.&#xD;
&#xD;
      Our team developed the Strong Together intervention which teaches self-advocacy skills in a&#xD;
      serious game platform. Patients vicariously respond to health challenges managing symptoms,&#xD;
      communicating with providers, and managing their health and are then exposed to the positive&#xD;
      and negative consequences of self-advocating or not, respectively. It is based on our team's&#xD;
      self-advocacy conceptual model, grounded in behavior change and educational theories, and&#xD;
      integrates multiple mechanisms to promote learning outcomes. Our valid, reliable self-report&#xD;
      self-advocacy measure captures the three dimensions of self-advocacy: informed&#xD;
      decision-making, strength through connection, and effective communication. Our pilot&#xD;
      randomized clinical trial (RCT) of the Strong Together intervention among N=70 women newly&#xD;
      diagnosed with advanced breast or gynecologic cancer demonstrated feasibility (82% completed&#xD;
      6-month surveys, 71% engaged in all intervention sessions) and intervention acceptability&#xD;
      (97% satisfied; 90% saw it as useful).&#xD;
&#xD;
      In the current study, the investigators will test the efficacy of the Strong Together&#xD;
      intervention compared with an enhanced care as usual group in a larger, more diverse sample&#xD;
      of women with advanced cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2022</start_date>
  <completion_date type="Anticipated">August 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in self-advocacy scores on the Female Self-Advocacy in Cancer Survivorship (FSACS) Scale at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The Female Self-Advocacy in Cancer Survivorship (FSACS) Scale is a 20-item, 6-point Likert-type scale (score range: 20-120). The scale is a validated measure of a woman with cancer's ability to engage in informed decision-making, strength through connection, and effective communication with healthcare providers. Higher scores indicate higher self-advocacy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in self-advocacy scores on the Female Self-Advocacy in Cancer Survivorship (FSACS) Scale at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The Female Self-Advocacy in Cancer Survivorship (FSACS) Scale is a 20-item, 6-point Likert-type scale (score range: 20-120). The scale is a validated measure of a woman with cancer's ability to engage in informed decision-making, strength through connection, and effective communication with healthcare providers. Higher scores indicate higher self-advocacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in quality of life scores on the Functional Assessment of Cancer Therapy - General (FACT-G) Scale at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The Functional Assessment of Cancer Therapy - General (FACT-G) is a 27-item, 5-point Likert-type scale (score range: 0-108). This scale captures physical, functional, social, and emotional well-being among patients with cancer. Higher scores indicate higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in quality of life scores on the Functional Assessment of Cancer Therapy - General (FACT-G) Scale at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The Functional Assessment of Cancer Therapy - General (FACT-G) is a 27-item, 5-point Likert-type scale (score range: 0-108). This scale captures physical, functional, social, and emotional well-being among patients with cancer. Higher scores indicate higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in symptom burden scores on the M.D. Anderson Symptom Inventory (MDASI) at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The M.D. Anderson Symptom Inventory (MDASI) is a 19-item, 11-point Likert-type scale consisting of two subscales (score range: 0-190. The first subscale assesses symptom severity of 13 common cancer- and treatment-related symptoms on a scale of 0 to 10. Higher scores indicate higher symptom severity. The second subscale assesses the degree to which symptoms interfere with daily life on a scale of 0 to 10. Higher scores indicate higher symptom interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in symptom burden scores on the M.D. Anderson Symptom Inventory (MDASI) at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The M.D. Anderson Symptom Inventory (MDASI) is a 19-item, 11-point Likert-type scale consisting of two subscales (score range: 0-190. The first subscale assesses symptom severity of 13 common cancer- and treatment-related symptoms on a scale of 0 to 10. Higher scores indicate higher symptom severity. The second subscale assesses the degree to which symptoms interfere with daily life on a scale of 0 to 10. Higher scores indicate higher symptom interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in patient-perceived patient-centeredness of care scores on the Patient Centeredness of Care Scale (PCCS) at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The Patient Centeredness of Care Scale (PCCS) is 14-item, 4-point Likert-type scale (score range: 0-42). This measure assesses patient perceptions of how patient-centered their oncologist interactions are, including the degree the oncologist explores the patient's health and illness experiences and finds common ground.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in patient-perceived patient-centeredness of care scores on the Patient Centeredness of Care Scale (PCCS) at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The Patient Centeredness of Care Scale (PCCS) is 14-item, 4-point Likert-type scale (score range: 0-42). This measure assesses patient perceptions of how patient-centered their oncologist interactions are, including the degree the oncologist explores the patient's health and illness experiences and finds common ground.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes from baseline in use of healthcare service utilization defined as hospital admissions, emergency room visits, and (un)planned clinic visits at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Electronic Medical Record and self-report of the number of times the patient has gone to the Emergency Department, been admitted to a hospital, and had (un)scheduled clinic visits within the past three months</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in use of healthcare service utilization defined as hospital admissions, emergency room visits, and (un)planned clinic visits at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Electronic Medical Record and self-report of the number of times the patient has gone to the Emergency Department, been admitted to a hospital, and had (un)scheduled clinic visits within the past three months</description>
  </other_outcome>
  <other_outcome>
    <measure>Intervention receipt</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Calculation of the time, duration, and intervention content used by participants.</description>
  </other_outcome>
  <other_outcome>
    <measure>Intervention mechanism usage</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Calculation of differences in primary and secondary outcome measures based on exposure to serious game mechanisms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Intervention mechanism usage</measure>
    <time_frame>Baseline and v6 months</time_frame>
    <description>Calculation of differences in primary and secondary outcome measures based on exposure to serious game mechanisms.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Self-Management</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Serious game intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive the Strong Together serious game program on a tablet computer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced care as usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive a paper-based self-advocacy guide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Strong Together serious game</intervention_name>
    <description>The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants receive weekly notifications for 12 weeks alerting them that a new serious game session is available and encourage them to complete one session per week.</description>
    <arm_group_label>Serious game intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Enhanced Care as Usual</intervention_name>
    <description>A self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.</description>
    <arm_group_label>Enhanced care as usual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  â‰¥18 years&#xD;
&#xD;
          -  Diagnosed with Stage III or IV gynecological or Stage IV breast cancer within the past&#xD;
             3 months being treated with non-curative intent&#xD;
&#xD;
          -  Have at least a 6-month life expectancy (as determined by their oncologist)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance score of 0 to 2 (per health record or&#xD;
             oncologist)&#xD;
&#xD;
          -  Able to read and write in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On hospice at the time of recruitment&#xD;
&#xD;
          -  Impaired cognition (per health record)&#xD;
&#xD;
          -  Other active, unstable mental health disorder&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Inclusion criteria are based on cancer diagnoses which primarily occur in women (gynecological and breast cancer)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Teresa H Thomas, PhD, RN</last_name>
    <phone>4126243799</phone>
    <email>t.thomas@pitt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Teresa H Thomas, PhD, RN</last_name>
      <phone>412-624-3799</phone>
      <email>t.thomas@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>Teresa H Thomas, PhD, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 20, 2021</study_first_submitted>
  <study_first_submitted_qc>March 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Teresa Thomas, PhD, RN</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Self-advocacy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

